Latest research
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Top papers this month · This week's roundup
Trending topics
IPD meta-analysis of 46 RCTs (285,124 participants): each 5 mm Hg systolic reduction lowered major cardiovascular events similarly with CKD (HR 0.91) and without (HR 0.90), across CKD stages 1–5, but less with CKD plus diabetes (HR 0.96).
Meta-analysisn = 285,124
Zeng et al. Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysisIn a Hong Kong cohort of 124,854 adults starting antidepressants, SSRI initiators had no significant difference in stroke risk vs non-SSRI initiators (HR 0.95, 95% CI 0.77-1.17); a meta-analysis with 5 other observational studies agreed (RR 0.94, 0.83-1.06).
Meta-analysisn = 124,854
Sun et al. Risk of stroke among individuals on selective serotonin reuptake inhibitors (SSRIs) versus non-SSRI antidepressants: a population-based retrospective cohort study and meta-analysisSystematic review of 13 studies (6 meta-analysed, n=5,657): circulating GDF-15 was higher in adults with depression than controls (SMD 0.39, 95% CI 0.19–0.58), with moderate-to-high heterogeneity; links with severity were inconsistent.
Meta-analysisn = 55,985
Jones-Murphy et al. Circulating Growth Differentiation Factor-15 (GDF-15) levels in depressive disorders - A systematic review and meta-analysis of the association between GDF-15 and depression in adult populationsSystematic review and meta-analysis of 15 studies (24,320 cases): severe endodontic flare-up incidence 2.83%; strongest risk factors were preoperative spontaneous pain (RR 5.83) and percussion pain (RR 3.45). Certainty of evidence low.
Meta-analysisn = 24,320 cases
Ohshima et al. Factors Associated With Endodontic Flare-Ups: A Systematic Review and Meta-AnalysisMeta-analysis of 24 studies (24,285 patients): physiology-guided deferral was associated with lower all-cause death, cardiovascular death and unplanned revascularisation than revascularisation; MACE and MI differences were not significant.
Meta-analysisn = 24,285
Lombardi et al. Cardiovascular Outcomes in Patients With Deferred and Performed Coronary Revascularization Based on Intracoronary Physiology: A Systematic Review and Meta-AnalysisMeta-analysis of 7 observational studies (21,244 patients with rheumatoid arthritis): selective JAK1 inhibitors were associated with lower discontinuation than pan-JAK inhibitors (HR 0.72), mainly for lack of efficacy (HR 0.68); adverse-event and infection stops were similar.
Meta-analysisn = 21,244
Lee et al. Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidenceMeta-analysis of 6 genome-wide association studies (4,710 AML cases, 12,938 controls) found a new pan-AML risk locus at 2p23.3, also linked to survival, plus subgroup-specific loci at 1q23.3, 2q33.3 and 2p21.
Meta-analysisn = 17,648
Ranasinghe et al. Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemiaSystematic review of 44 trials (9704 adults; 37 trials meta-analysed for intubation) in acute hypoxaemic respiratory failure: vs standard oxygen, CPAP (OR 0.45), HFNC (OR 0.61) and bilevel NIPPV (OR 0.60) probably reduce intubation; CPAP and HFNC may reduce mortality.
Meta-analysisn = 9,704
Lee et al. Non-invasive respiratory supports and criteria for intubation in randomised trials of acute hypoxaemic respiratory failure: a systematic review and network meta-analysisRCT in children with septic shock (8482 of 9041 analysed): balanced fluid vs 0.9% saline did not change 30-day major adverse kidney events (3.4% vs 3.0%; RR 1.10, 95% CI 0.88–1.40); hyperchloraemia was less common (31.4% vs 49.0%), hyperlactataemia more (19.8% vs 16.7%).
RCTn = 9,041
Balamuth et al. Balanced Fluid or 0.9% Saline in Children Treated for Septic ShockNetwork meta-analysis of 18 RCTs (7281 adults with migraine and prior preventive failure): vs placebo, fremanezumab, eptinezumab, galcanezumab, atogepant and erenumab may most reduce monthly migraine days (MD −2.20 to −3.35); low-certainty evidence.
Meta-analysisn = 7,281
Khalili et al. Effectiveness and tolerability of pharmacological prophylaxis in migraine patients with prior preventive treatment failure: A systematic review and network meta-analysis of randomized controlled trials